A randomized phase II study of cabazitaxel (CAB) vs (ABI) abiraterone or (ENZ) enzalutamide in poor prognosis metastatic castration-resistant prostate cancer (mCRPC) Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Chi, KN
  • Taavitsainen, S
  • Iqbal, N
  • Ferrario, C
  • Ong, M
  • Wadhwa, D
  • Hotte, Sebastien
  • Lo, G
  • Tran, B
  • Azad, A
  • Wood, L
  • Gingerich, JR
  • North, S
  • Pezaro, CV
  • Ruether, D
  • Sridhar, SS
  • Annala, M
  • Bacon, J
  • Wyatt, AW

publication date

  • October 2018